Skip to content
Screener

Vir Biotechnology, Inc. VIR Operating Lease Liabilities (Current)

Operating Lease Liabilities (Current) at other companies

Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$37.8M+24.8%
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
$722K+30.6%
Biohaven logo
BiohavenBHVN
$5.9M+25.3%
Assembly Biosciences logo
Assembly BiosciencesASMB
$590K+11.5%
Arbutus Biopharma Corporation logo
Arbutus Biopharma CorporationABUS
$631K+12.1%
Krystal Biotech, Inc. logo
Krystal Biotech, Inc.KRYS
$1.8M+32.2%

Other financials

Income statement

See full
Revenue$238.9M+19,583%
Gross profit$238.9M+19,763%
Operating income$73.5M+162%
Net income$80.1M+172%
EPS (diluted)$0.47+159%

Balance sheet

See full
Cash & equivalents$287.6M-6.1%
Total debt$93.3M-8.8%
Total equity$982.5M+3.7%
Total assets$1.2B+1.9%

Cash flow

See full
Operating cash flow-$132.4M-69.5%
CapEx$32.0K-98.7%
Free cash flow-$132.8M-66.5%

Valuation

See full
Market cap$1.49B+151%
Enterprise value$1.3B+232%
P/S4.9×-26.4×

Profitability

See full
Gross margin96.1%-2.7pp
Operating margin-92.4%-45.5pp
Net margin-83%-40.9pp
FCF margin-686.5%-273pp

Returns & leverage

See full
Return on equity-26.1%-7.9pp
Debt / equity0.1×0.0×
Current ratio-1.0×

Where this comes from

Reported directly by Vir Biotechnology, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseLiabilityCurrent.

The source filing: Vir Biotechnology, Inc.’s 10-Q, filed August 5, 2026. Open the filing →

Filed
Aug 5, 2026, 5:20 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001628280-26-053549

FAQ

What is Vir Biotechnology, Inc.'s operating lease liabilities (current)?
Vir Biotechnology, Inc. (VIR) reported operating lease liabilities (current) of $9.14M in Q2 2026.
How has Vir Biotechnology, Inc.'s operating lease liabilities (current) changed year-over-year?
Vir Biotechnology, Inc.'s operating lease liabilities (current) increased by 3.5% year-over-year, from $8.83M to $9.14M.
What is the long-term trend for Vir Biotechnology, Inc.'s operating lease liabilities (current)?
Over 5 years (2020 to 2025), Vir Biotechnology, Inc.'s operating lease liabilities (current) has grown at a 19.4% compound annual growth rate (CAGR), from $3.63M to $8.8M.
What does operating lease liabilities (current) mean?
The current portion of operating lease obligations due within one year, representing committed future lease payments under ASC 842.

Ask your AI about Vir Biotechnology, Inc.'s operating lease liabilities (current).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude